<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Erythromelalgia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Erythromelalgia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Erythromelalgia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark DP Davis, MD, FAAD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey Callen, MD, FACP, FAAD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 03, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2230264691"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Erythromelalgia is a rare, acquired or (very rarely) inherited clinical syndrome of intermittently red, hot, painful extremities  (<a class="graphic graphic_picture graphicRef110935 graphicRef130422 graphicRef110936 graphicRef130423 graphicRef110937 graphicRef110938 graphicRef110939" href="/d/graphic/110935.html" rel="external">picture 1A-G</a>). The syndrome usually affects the lower extremities (predominantly the feet) but may also involve the upper extremities (predominantly hands) and rarely concomitantly involves the face. Patients instinctively try to relieve symptoms by cooling the involved areas with fans, cold water, or ice.<strong> </strong></p><p>There is no cure for erythromelalgia; therefore, treatment is focused on improving symptoms. Many patients can be successfully managed with behavioral interventions, topical medications, and <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>. Other interventions may be beneficial when these measures are insufficient.</p><p>The epidemiology, clinical features, diagnosis, and management of erythromelalgia will be reviewed here.</p><p class="headingAnchor" id="H3452338868"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Epidemiologic data on erythromelalgia are limited, but erythromelalgia appears to be rare [<a href="#rid1">1-4</a>]. Population-based studies from the United States, Sweden, and Norway have found incidence rates of less than 2 per 100,000 people per year [<a href="#rid1">1-3</a>]. </p><p>Erythromelalgia is more common in women than in men and most often occurs in adults [<a href="#rid1">1,2</a>]. In a population-based study in Olmsted County, Minnesota, the age-adjusted incidence rates were 2 (95% CI 1.2-2.7) per 100,000 women and 0.6 (95% CI 0.1-1.1) per 100,000 men [<a href="#rid1">1</a>]. The median age at diagnosis was 61 years (range, 16 to 90 years). Among 27 patients with erythromelalgia identified in a Swedish study, the median age was 49 years (interquartile range 34 to 68 years) [<a href="#rid2">2</a>].</p><p>Erythromelalgia is exceedingly rare in children. In the largest series reported of pediatric erythromelalgia, which included 32 patients (including 22 females) evaluated at an academic medical center between 1970 to 2007, the mean age was 14 years (range, 5 to 18 years) and the mean time to diagnosis was 5.2 years [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H1215244039"><span class="h1">ASSOCIATED DISEASES</span><span class="headingEndMark"> — </span>Although originally described in association with myeloproliferative diseases (eg, essential thrombocytosis, chronic myelogenous leukemia, polycythemia vera, myelofibrosis), erythromelalgia appears to be associated with underlying myeloproliferative diseases in less than 10 percent of cases [<a href="#rid6">6</a>]. A diagnosis of myeloproliferative disease may precede, follow, or coincide with the development of erythromelalgia. (See  <a class="medical medical_review" href="/d/html/4511.html" rel="external">"Overview of the myeloproliferative neoplasms"</a> and  <a class="medical medical_review" href="/d/html/4491.html" rel="external">"Clinical manifestations, pathogenesis, and diagnosis of essential thrombocythemia"</a> and  <a class="medical medical_review" href="/d/html/4517.html" rel="external">"Clinical manifestations and diagnosis of polycythemia vera"</a>.)</p><p>A variety of other comorbidities (eg, autoimmune diseases, infections, neoplasms, neurologic diseases), pregnancy, and drug exposures have been reported in patients with erythromelalgia in case reports. However, the relationship between erythromelalgia and these diseases is unclear.</p><p class="headingAnchor" id="H2247376007"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>Some authors have used "primary erythromelalgia" to refer to idiopathic or inherited erythromelalgia and "secondary erythromelalgia" to refer to erythromelalgia that occurs in the setting of an underlying disease associated with erythromelalgia. However, the use of these terms is debated because of the uncertainty regarding the relationship between erythromelalgia and comorbidities other than myeloproliferative disease. Because of this confusion, the author suggests avoidance of the terms "primary" or "secondary" when referring to erythromelalgia.</p><p class="headingAnchor" id="H926459480"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The pathogenesis of erythromelalgia is not fully understood. Vascular, neural, and genetic factors may play roles:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vascular factors</strong> – A role for vascular changes in the pathogenesis of erythromelalgia is suggested by the finding of increased blood flow (up to 10-fold increase as measured by laser Doppler) and temperature in affected areas during symptomatic episodes. Paradoxically, transcutaneous oximetry stays unchanged or is decreased [<a href="#rid7">7,8</a>]. Microvascular arteriovenous shunting is a proposed mechanism for a deficit in skin nutritive perfusion and skin hypoxia [<a href="#rid9">9,10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuropathy</strong> – There appears to be a strong association between erythromelalgia and both large and small fiber neuropathy, suggesting a role for neuropathy in the development of symptoms. Large fiber neuropathy is supported by the finding of abnormal electromyography in up to 60 percent of patients; small fiber neuropathy is supported by the detection of abnormal functional testing of small fibers: abnormal quantitative sudomotor axon reflex tests in up to 80 percent of patients and abnormal thermoregulatory sweat testing in up to 90 percent of patients [<a href="#rid7">7,8,11,12</a>]. Intriguingly, skin biopsies show decreased epidermal nerve fiber density in only 10 percent, suggesting that the small fiber neuropathy is a functional rather than structural/anatomic neuropathy [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics</strong> – Inherited erythromelalgia (MIM #133020) is an autosomal dominant disorder that accounts for a small proportion of cases of erythromelalgia [<a href="#rid14">14,15</a>]. In the largest series of consecutive patients with erythromelalgia (n = 168), only six patients (4 percent) had a first-degree relative with erythromelalgia, including three members of the same family [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1">Inherited erythromelalgia is caused by a heterozygous mutation in the <em>SCN9A</em> gene on chromosome 2q24, which encodes a voltage-gated sodium channel. The mutant channels confer hyperexcitability to peripheral sensory and sympathetic neurons, an effect that may contribute to the intense pain associated with erythromelalgia [<a href="#rid16">16,17</a>]. Exonic mutations in <em>SCN9A</em> (NaV1.7) are found in a minority of patients with erythromelalgia [<a href="#rid18">18-20</a>].</p><p></p><p class="headingAnchor" id="H1344203418"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Characteristic precipitating factors for episodes of erythromelalgia include an increase in ambient heat or exercise. </p><p class="headingAnchor" id="H3163644678"><span class="h2">Signs and symptoms</span><span class="headingEndMark"> — </span>During episodes, affected areas (typically distal extremities) become red or violaceous, hot, and painful  (<a class="graphic graphic_picture graphicRef110935 graphicRef130422 graphicRef110936 graphicRef130423 graphicRef110937 graphicRef110938 graphicRef110939" href="/d/graphic/110935.html" rel="external">picture 1A-G</a>). Swelling occasionally occurs. The episodes are intermittent and generally last for minutes to hours before resolving. </p><p>Episodes occur in association with precipitating factors (eg, increase in ambient heat or exercise) and often occur at night (perhaps associated with increased ambient heat in bed). The number of episodes per day is highly variable. </p><p>Erythromelalgia affects the feet (eg, toes, soles of the feet, dorsum of the feet, or entire feet) in approximately 90 percent of patients [<a href="#rid6">6</a>]. The fingers, dorsal hands, or entire hands are affected in approximately 25 percent. Occasionally, erythromelalgia extends to involve more proximal portions of the extremities. Symptoms are usually symmetrical but may be unilateral or more prominent on one side of the body.</p><p>Head and neck involvement (eg, ears, nose, cheeks) is infrequent, occurring in 2 to 3 percent of patients. Whether painful flushing of the face (eg, ears, nose, cheeks) alone can be considered to represent erythromelalgia is debated; we favor a diagnosis of erythromelalgia only if feet and/or hands are also involved [<a href="#rid21">21</a>].</p><p>Pain during episodes is most commonly described as a burning sensation. The pain can be extreme and may seem out of proportion to the observed clinical findings [<a href="#rid6">6</a>].</p><p>Between episodes, the characteristic features of redness, heat, and pain in affected body areas are absent. However, in up to two-thirds of patients, the affected areas are cool to the touch and purple in color (acrocyanosis) between episodes  (<a class="graphic graphic_picture graphicRef110940" href="/d/graphic/110940.html" rel="external">picture 2</a>). Features of Raynaud phenomenon also have been reported [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H2699414384"><span class="h2">Clinical course</span><span class="headingEndMark"> — </span>Erythromelalgia usually remains intermittent. Some patients report that symptoms become more frequent and prolonged over months to years. Occasionally, episodes of erythromelalgia become continuous.</p><p class="headingAnchor" id="H2551635137"><span class="h2">Cooling behaviors</span><span class="headingEndMark"> — </span>A characteristic feature of erythromelalgia is patient use of cooling techniques to achieve symptom relief. In addition to stopping precipitating actions (eg, stopping exercise, decreasing ambient heat by decreasing room temperature) upon onset of an episode, patients often engage in:</p><p class="bulletIndent1"><span class="glyph">●</span>Use of fans on affected area</p><p class="bulletIndent1"><span class="glyph">●</span>Immersion of the affected area in ice water, snow, or equivalents </p><p class="bulletIndent1"><span class="glyph">●</span>Application of ice packs, bags of frozen vegetables, battery-powered cooling socks or gloves</p><p></p><p>Potential complications of cooling techniques that may be present in patients with erythromelalgia include "windburn" from fans, signs and symptoms of frostbite secondary to overuse of ice  (<a class="graphic graphic_picture graphicRef110942" href="/d/graphic/110942.html" rel="external">picture 3</a>), Raynaud phenomenon, and acrocyanosis associated with cold exposure. Chronic immersion of the feet in water may lead to skin maceration, edema, and ulcerations, also known as "immersion foot" or "trench foot" [<a href="#rid23">23</a>]. </p><p class="headingAnchor" id="H1047956084"><span class="h2">Quality of life</span><span class="headingEndMark"> — </span>Erythromelalgia can have a profound negative effect on quality of life. Patients usually avoid precipitating exposures (eg, exercise, warm rooms), which in severe cases can result in becoming housebound, anxious, or depressed secondary to fear of precipitating episodes. Patients with severe symptoms may need to use a wheelchair or remain in bed [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H1378661750"><span class="h1">PATHOLOGY</span><span class="headingEndMark"> — </span>Skin biopsies of affected areas show nonspecific findings [<a href="#rid24">24</a>]. Examples of reported findings include smooth muscle cell hyperplasia and/or swelling in arterioles; thickened, arteriolar basement membranes; mild, perivascular, lymphocytic inflammation; and mild, perivascular edema [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H1025602894"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Erythromelalgia is a clinical syndrome. The diagnosis is made based upon recognition of characteristic signs and symptoms (ie, intermittent episodes of red, hot, painful extremities that may be precipitated by heat or exercise and improve with cooling). Asking the patient to take photographs of the affected areas during an episode is helpful for confirming redness in patients who are asymptomatic at the time of clinical evaluation (the majority of patients) [<a href="#rid22">22</a>]. </p><p>Skin biopsies do not aid in the diagnosis of erythromelalgia [<a href="#rid24">24</a>]; the usefulness of biopsies is limited to ruling out other suspected conditions. There are no serologic tests that confirm the diagnosis. </p><p class="headingAnchor" id="H76875081"><span class="h1">ADDITIONAL EVALUATION</span><span class="headingEndMark"> — </span>Given the association of erythromelalgia with myeloproliferative disease, a complete blood count with differential should be obtained to assess for signs of underlying myeloproliferative disease. (See <a class="local">'Associated diseases'</a> above.) </p><p>Additional tests, such as electromyography, nerve conduction velocity, and tests for small fiber neuropathy (eg, quantitative sudomotor axon reflex test or thermoregulatory sweat testing), are often abnormal in patients with erythromelalgia, but routine performance of these tests is not essential. The results of these tests do not influence the management of erythromelalgia but provide support for the use of medications for neuropathy in patients with erythromelalgia. (See <a class="local">'Pathogenesis'</a> above and <a class="local">'Pharmacologic therapy'</a> below.)</p><p class="headingAnchor" id="H1286462059"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of erythromelalgia includes<strong> </strong>other causes of extremity pain, such as large or small fiber neuropathy (which can also be a comorbid condition with erythromelalgia) and peripheral artery disease; other causes of red or discolored extremities, such as lipodermatosclerosis, acrocyanosis, Raynaud phenomenon, and cellulitis; and metabolic diseases, such as Fabry disease. The occurrence of red, hot extremities in conjunction with painful episodes distinguishes erythromelalgia form these diseases.</p><p>Of note, acrocyanosis and Raynaud phenomenon can occur in patients with erythromelalgia [<a href="#rid22">22</a>]. In particular, the hyperemic phase of Raynaud phenomenon is characterized by skin blushing and can be mistaken for an episode of erythromelalgia. Moreover, Raynaud phenomenon is often triggered by cold (rather than heat) exposure. (See  <a class="medical medical_review" href="/d/html/7543.html" rel="external">"Clinical manifestations and diagnosis of Raynaud phenomenon"</a>.)</p><p class="headingAnchor" id="H2289927976"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>There is no cure for erythromelalgia. Therefore, interventions are directed at improving quality of life and reducing symptoms. </p><p>Data on treatments for erythromelalgia are primarily limited to case reports and small case series, precluding conclusions regarding the best approach to treatment. Treatment typically involves a combination of nonpharmacologic interventions, management of identified underlying myeloproliferative or neurologic disease, pharmacologic interventions, and patient counseling. Pain rehabilitation programs may be useful for patients with debilitating symptoms. A summary of our typical approach to treatment is provided. (See <a class="local">'Our approach'</a> below.)</p><p class="headingAnchor" id="H2252933624"><span class="h2">Nonpharmacologic measures</span><span class="headingEndMark"> — </span>Nonpharmacologic measures should be included in the management of patients with erythromelalgia as they can reduce symptoms and may reduce requirements for pharmacologic therapy. In our experience, the following interventions can be helpful for alleviating episodes:</p><p class="bulletIndent1"><span class="glyph">●</span>Avoidance of precipitating factors (increased ambient heat, exercise) as much as possible while maintaining as normal a lifestyle as possible</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Exposure of the affected area to cool water for short periods of time (eg, 5 to 10 minutes every one to two hours)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Limb elevation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fan use for short periods of time (5 to 10 minutes every one to two hours)</p><p></p><p>Cooling measures can result in complications if used inappropriately or excessively [<a href="#rid23">23</a>]. Patients should avoid applying ice or very cold water directly to the skin. (See <a class="local">'Cooling behaviors'</a> above.)</p><p class="headingAnchor" id="H1177149997"><span class="h2">Pharmacologic therapy</span><span class="headingEndMark"> — </span>A variety of topical and systemic therapies have been used for erythromelalgia. Efficacy data are limited and insufficient for conclusions on the best approach to treatment and best treatment regimens. Comparative trials have not been performed. </p><p>For most patients, nonpharmacologic measures and topical pain-relieving medications improve symptoms, although the response to individual treatments varies widely. </p><p class="headingAnchor" id="H3341032005"><span class="h3">Topical treatments</span><span class="headingEndMark"> — </span>Case series and retrospective studies suggest that topical <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> (we prefer lidocaine patches since they gradually release lidocaine over a prolonged period [<a href="#rid25">25-27</a>]) and compounded <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a> and <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">ketamine</a> [<a href="#rid28">28,29</a>] may improve the pain associated with erythromelalgia. Benefit from topical <a class="drug drug_general" data-topicid="8840" href="/d/drug information/8840.html" rel="external">capsaicin</a> is described in a case report [<a href="#rid30">30</a>]. Other topical treatments that have been suggested, but not formally studied, include nonprescription pain-relieving rubs or patches, <a class="drug drug_general" data-topicid="9348" href="/d/drug information/9348.html" rel="external">diclofenac</a> 1% gel, and <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a> 6% ointment.</p><p>Topical vasoactive medications may be helpful for improving redness, such as compounded <a class="drug drug_general" data-topicid="9651" href="/d/drug information/9651.html" rel="external">midodrine</a> 0.2% [<a href="#rid31">31</a>]. In theory, topical <a class="drug drug_general" data-topicid="9163" href="/d/drug information/9163.html" rel="external">brimonidine</a> tartrate 0.33% and topical <a class="drug drug_general" data-topicid="10186" href="/d/drug information/10186.html" rel="external">oxymetazoline</a> 0.05% might help.</p><p class="headingAnchor" id="H1177385928"><span class="h3">Systemic treatments</span><span class="headingEndMark"> — </span>Systemic therapy also may be beneficial. <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">Aspirin</a> is a common initial treatment that may be particularly useful for patients with myeloproliferative disease based upon data from case reports and case series [<a href="#rid32">32-34</a>]. In patients with myeloproliferative disease, aspirin may relieve symptoms within days. Other systemic therapies are implemented when behavioral interventions, topical therapies, and aspirin are insufficient. </p><p>Common treatments described as beneficial in case reports are agents used for neuropathic pain, including <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a> [<a href="#rid35">35-39</a>], <a class="drug drug_general" data-topicid="9473" href="/d/drug information/9473.html" rel="external">pregabalin</a> [<a href="#rid40">40,41</a>], <a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">venlafaxine</a> [<a href="#rid42">42</a>], and oral <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a> [<a href="#rid43">43</a>]. Oral <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> appeared beneficial in a double-blind, crossover, nonrandomized study in which 21 patients were treated with placebo for six weeks, followed by misoprostol for six weeks [<a href="#rid44">44</a>]. </p><p>Additional systemic agents that have appeared useful for improving symptoms in small numbers of patients include <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a> [<a href="#rid45">45</a>], sodium channel blockers (<a class="drug drug_general" data-topicid="9648" href="/d/drug information/9648.html" rel="external">mexiletine</a> [<a href="#rid46">46-52</a>], mexiletine with intravenous <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> [<a href="#rid52">52</a>], <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> [<a href="#rid37">37,53</a>]), a variety of vasoactive drugs (beta blockers, calcium antagonists [eg, <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a>] [<a href="#rid6">6,54</a>], sodium <a class="drug drug_general" data-topicid="9707" href="/d/drug information/9707.html" rel="external">nitroprusside</a> [<a href="#rid55">55-58</a>], high-dose oral magnesium [<a href="#rid59">59</a>], and <a class="drug drug_general" data-topicid="9311" href="/d/drug information/9311.html" rel="external">cyproheptadine</a> [<a href="#rid60">60</a>]), and intravenous immunoglobulin [<a href="#rid61">61</a>]. </p><p>There have been reports of benefit from systemic glucocorticoids in patients with sudden-onset, severe erythromelalgia who were treated within weeks after the onset of symptoms [<a href="#rid62">62</a>]. In a retrospective study in which 17 of 31 patients (55 percent) treated with systemic glucocorticoids for erythromelalgia had improvement of symptoms, the median duration of disease prior to treatment was shorter among responders (3 months [range 3 to 12 months]) compared with nonresponders (24 months [range 17 to 45 months]) [<a href="#rid62">62</a>]. </p><p>Rarely, epidural anesthesia or surgical intervention is used for erythromelalgia. Benefit from epidural <a class="drug drug_general" data-topicid="9169" href="/d/drug information/9169.html" rel="external">bupivacaine</a> hydrochloride [<a href="#rid63">63-65</a>] and thoracic or lumbar sympathectomy is described in case reports [<a href="#rid66">66-71</a>].</p><p class="headingAnchor" id="H4085623276"><span class="h2">Treatment of myeloproliferative disease</span><span class="headingEndMark"> — </span>Although rapid responses to <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> can occur in patients with underlying myeloproliferative disease, the underlying myeloproliferative disease also should be treated if possible. Limited data from case reports and case series suggest that treatment of myeloproliferative disease may contribute to improvement in erythromelalgia [<a href="#rid32">32,33</a>]. (See <a class="local">'Pharmacologic therapy'</a> above and  <a class="medical medical_review" href="/d/html/4511.html" rel="external">"Overview of the myeloproliferative neoplasms"</a>.)</p><p class="headingAnchor" id="H1169209731"><span class="h2">Pain rehabilitation programs</span><span class="headingEndMark"> — </span>In our experience, patients with refractory, debilitating pain may benefit from pain rehabilitation programs. Pain rehabilitation programs use a multidisciplinary and behavioral therapy approach to help restore physical activities and improve the quality of life for patients with chronic pain. In an uncontrolled study of eight patients with incapacitating erythromelalgia who underwent a pain rehabilitation program, scores on all measures of physical and emotional functioning improved [<a href="#rid72">72</a>].</p><p class="headingAnchor" id="H10271945"><span class="h2">Patient counseling</span><span class="headingEndMark"> — </span>Fear of precipitating episodes of erythromelalgia may prompt patients to dramatically alter their lifestyles to avoid potential triggers for symptoms. Provided pain is adequately controlled, patients should be encouraged to engage in a normal lifestyle as much as possible. There are no data to show that engaging in precipitating activities will worsen the long-term outcome of erythromelalgia. Many patients can tolerate swimming as a form of exercise that may be less likely to precipitate episodes.</p><p>Support groups, such as the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Ferythromelalgia.org%2F&amp;token=nQU5mgxP4wnPb%2F3C4BcHmg9u%2BweAAiy7AIxV8Y9Un1U24x3Di3uODTVZ103%2FwoD6&amp;TOPIC_ID=13766" target="_blank">Erythromelalgia Association</a>, can be a valuable resource for patients. </p><p class="headingAnchor" id="H483747784"><span class="h2">Our approach</span><span class="headingEndMark"> — </span>Given the paucity of data on the management of erythromelalgia, various approaches to treatment are reasonable. Our typical approach for adults with erythromelalgia is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Step 1</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Counseling regarding nonpharmacologic measures to minimize symptoms. (See <a class="local">'Nonpharmacologic measures'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">Aspirin</a> (325 mg per day, discontinue after one month if no response; aspirin may be particularly beneficial in patients with myeloproliferative disease).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Trial of topical therapies:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Compounded <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a> 2% combined with <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">ketamine</a> 0.5% in a Lipoderm base (applied three times daily as needed)</p><p></p><p class="bulletIndent3"><strong>Or</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Compounded <a class="drug drug_general" data-topicid="9651" href="/d/drug information/9651.html" rel="external">midodrine</a> 0.2% cream (applied three times daily as needed)</p><p></p><p class="bulletIndent3"><strong>Or</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">Lidocaine</a> patch (up to three patches applied to affected areas for 12 hours every 24-hour period)</p><p></p><p class="bulletIndent2">Patients should be treated with topical therapies for at least two to four weeks to assess efficacy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Treatment of underlying myeloproliferative disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Step 2 (patients who fail to respond adequately to step 1)</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Initiation of other systemic treatments:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">Gabapentin</a> (300 mg once daily at bedtime; may be titrated gradually up to a maximum of 2400 mg per day as needed and as tolerated)</p><p></p><p class="bulletIndent3"><strong>Or</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9473" href="/d/drug information/9473.html" rel="external">Pregabalin</a> (75 mg twice daily; may be titrated up to 300 mg twice daily as needed and as tolerated)</p><p></p><p class="bulletIndent3"><strong>Or</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">Venlafaxine</a> (75 mg per day [in two to three divided doses])</p><p></p><p class="bulletIndent2">Patients should be treated with these agents for at least two to four months to assess efficacy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Step 3 (patients who fail to respond adequately to step 1 and step 2)</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Consider other medications (eg, <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a> [<a href="#rid43">43</a>], <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a>, <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a> [<a href="#rid45">45</a>], sodium channel blockers [<a class="drug drug_general" data-topicid="9648" href="/d/drug information/9648.html" rel="external">mexiletine</a> [<a href="#rid46">46-52</a>], <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> [<a href="#rid37">37,53</a>]]) (see <a class="local">'Pharmacologic therapy'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pain rehabilitation (see <a class="local">'Pain rehabilitation programs'</a> above)</p><p></p><p class="headingAnchor" id="H3269713969"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Prognostic data on erythromelalgia are limited. In a review of 168 patients with erythromelalgia, of the 94 patients available for a follow-up questionnaire (mean follow up 8.7 years [range 1.3 to 20 years]), 30 (32 percent) reported worsening of symptoms, 25 (27 percent) reported stable symptoms, 29 (31 percent) reported decreased symptoms, and 10 (11 percent) had experienced disappearance of symptoms [<a href="#rid6">6</a>]. Kaplan-Meier survival curves revealed a decrease in survival compared with that expected in persons of similar age and of the same sex. Notably, three patients committed suicide.</p><p class="headingAnchor" id="H3861446361"><span class="h1">FOLLOW-UP</span><span class="headingEndMark"> — </span>The frequency of clinical follow-up for erythromelalgia is dependent upon the response to treatment. Once disease is reasonably controlled, patients can return for evaluation as needed. </p><p>Patients with erythromelalgia should be monitored for the development of myeloproliferative disease. We obtain a complete blood count with differential once yearly.</p><p class="headingAnchor" id="H1121188992"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Erythromelalgia is a rare syndrome characterized by the intermittent occurrence of red, hot, painful extremities  (<a class="graphic graphic_picture graphicRef110935 graphicRef130422 graphicRef110936 graphicRef130423 graphicRef110937 graphicRef110938 graphicRef110939" href="/d/graphic/110935.html" rel="external">picture 1A-G</a>). Erythromelalgia most often occurs in adults and is more common in women than in men. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Erythromelalgia is associated with myeloproliferative disease in less than 10 percent of affected patients. A diagnosis of myeloproliferative disease may precede, follow, or occur concurrently with a diagnosis of erythromelalgia. The relationship between erythromelalgia and other systemic diseases is unclear. (See <a class="local">'Associated diseases'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The pathogenesis of erythromelalgia is not well understood. Vascular, neural, and genetic factors may play roles. A small subset of patients with erythromelalgia have inherited erythromelalgia. Inherited erythromelalgia is an autosomal dominant disorder caused by mutations in the <em>SCN9A</em> gene. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased ambient heat and exercise are common precipitators of episodes of erythromelalgia. During episodes, the affected areas become red, hot, and painful. The feet are the most common sites of involvement. Symptoms are typically bilateral, and episodes may last from seconds to hours. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of erythromelalgia is made based upon the recognition of the classic signs and symptoms. Photographs of the red extremities are helpful in confirming the history and for documenting the redness  (<a class="graphic graphic_picture graphicRef110935 graphicRef130422 graphicRef110936 graphicRef130423 graphicRef110937 graphicRef110938 graphicRef110939" href="/d/graphic/110935.html" rel="external">picture 1A-G</a>). The histopathologic findings of erythromelalgia are nonspecific, and no serologic tests confirm the diagnosis. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with erythromelalgia should be evaluated for myeloproliferative disease. Patients without evidence for myeloproliferative disease at the time of diagnosis should be monitored over time for the development of myeloproliferative disease. (See <a class="local">'Additional evaluation'</a> above and <a class="local">'Follow-up'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Data on treatment of erythromelalgia are limited, and responses to individual treatments vary widely. We suggest an initial therapeutic approach that includes patient counseling regarding methods to minimize symptoms, topical therapy, and <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). For patients with underlying myeloproliferative disease, we also suggest treatment of the myeloproliferative disease (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Management'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Reed KB, Davis MD. Incidence of erythromelalgia: a population-based study in Olmsted County, Minnesota. J Eur Acad Dermatol Venereol 2009; 23:13.</a></li><li><a class="nounderline abstract_t">Alhadad A, Wollmer P, Svensson A, Eriksson KF. Erythromelalgia: Incidence and clinical experience in a single centre in Sweden. Vasa 2012; 41:43.</a></li><li class="breakAll">Kvernebo K. Incidence and prevalence. In: Erythromelalgia: A Condition Caused by Microvascular Arteriovenous Shunting, VASA, 1998. Vol 51, p.13.</li><li><a class="nounderline abstract_t">Friberg D, Chen T, Tarr G, van Rij A. Erythromelalgia? A clinical study of people who experience red, hot, painful feet in the community. Int J Vasc Med 2013; 2013:864961.</a></li><li><a class="nounderline abstract_t">Cook-Norris RH, Tollefson MM, Cruz-Inigo AE, et al. Pediatric erythromelalgia: a retrospective review of 32 cases evaluated at Mayo Clinic over a 37-year period. J Am Acad Dermatol 2012; 66:416.</a></li><li><a class="nounderline abstract_t">Davis MD, O'Fallon WM, Rogers RS 3rd, Rooke TW. Natural history of erythromelalgia: presentation and outcome in 168 patients. Arch Dermatol 2000; 136:330.</a></li><li><a class="nounderline abstract_t">Sandroni P, Davis MD, Harper CM, et al. Neurophysiologic and vascular studies in erythromelalgia: a retrospective analysis. J Clin Neuromuscul Dis 1999; 1:57.</a></li><li><a class="nounderline abstract_t">Davis MD, Sandroni P, Rooke TW, Low PA. Erythromelalgia: vasculopathy, neuropathy, or both? A prospective study of vascular and neurophysiologic studies in erythromelalgia. Arch Dermatol 2003; 139:1337.</a></li><li><a class="nounderline abstract_t">Mork C, Asker CL, Salerud EG, Kvernebo K. Microvascular arteriovenous shunting is a probable pathogenetic mechanism in erythromelalgia. J Invest Dermatol 2000; 114:643.</a></li><li><a class="nounderline abstract_t">Mørk C, Kvernebo K, Asker CL, Salerud EG. Reduced skin capillary density during attacks of erythromelalgia implies arteriovenous shunting as pathogenetic mechanism. J Invest Dermatol 2002; 119:949.</a></li><li><a class="nounderline abstract_t">Davis MD, Genebriera J, Sandroni P, Fealey RD. Thermoregulatory sweat testing in patients with erythromelalgia. Arch Dermatol 2006; 142:1583.</a></li><li><a class="nounderline abstract_t">Genebriera J, Michaels JD, Sandroni P, Davis MD. Results of computer-assisted sensory evaluation in 41 patients with erythromelalgia. Clin Exp Dermatol 2012; 37:350.</a></li><li><a class="nounderline abstract_t">Mantyh WG, Dyck PJB, Dyck PJ, et al. Epidermal Nerve Fiber Quantification in Patients With Erythromelalgia. JAMA Dermatol 2017; 153:162.</a></li><li><a class="nounderline abstract_t">Burbank MK, Spittell JA Jr., Fairbairn JF II. Familial erythromelalgia: genetic and physiologic observations (abstract). J Lab Clin Med 1966; 68:861.</a></li><li><a class="nounderline abstract_t">Finley WH, Lindsey JR Jr, Fine JD, et al. Autosomal dominant erythromelalgia. Am J Med Genet 1992; 42:310.</a></li><li><a class="nounderline abstract_t">Cummins TR, Dib-Hajj SD, Waxman SG. Electrophysiological properties of mutant Nav1.7 sodium channels in a painful inherited neuropathy. J Neurosci 2004; 24:8232.</a></li><li><a class="nounderline abstract_t">McDonnell A, Schulman B, Ali Z, et al. Inherited erythromelalgia due to mutations in SCN9A: natural history, clinical phenotype and somatosensory profile. Brain 2016; 139:1052.</a></li><li><a class="nounderline abstract_t">Klein CJ, Wu Y, Kilfoyle DH, et al. Infrequent SCN9A mutations in congenital insensitivity to pain and erythromelalgia. J Neurol Neurosurg Psychiatry 2013; 84:386.</a></li><li><a class="nounderline abstract_t">Zhang Z, Schmelz M, Segerdahl M, et al. Exonic mutations in SCN9A (NaV1.7) are found in a minority of patients with erythromelalgia. Scand J Pain 2014; 5:217.</a></li><li><a class="nounderline abstract_t">Arthur L, Keen K, Verriotis M, et al. Pediatric Erythromelalgia and SCN9A Mutations: Systematic Review and Single-Center Case Series. J Pediatr 2019; 206:217.</a></li><li><a class="nounderline abstract_t">Davis MDP. Facial erythromelalgia? J Am Acad Dermatol 2018; 78:e127.</a></li><li><a class="nounderline abstract_t">Davis MD, Wilkins F, Rooke TW. Between episodes of erythromelalgia: a spectrum of colors. Arch Dermatol 2006; 142:1085.</a></li><li><a class="nounderline abstract_t">Davis MD. Immersion foot associated with the overuse of ice, cold water, and fans: a distinctive clinical presentation complicating the syndrome of erythromelalgia. J Am Acad Dermatol 2013; 69:169.</a></li><li><a class="nounderline abstract_t">Davis MD, Weenig RH, Genebriera J, et al. Histopathologic findings in primary erythromelalgia are nonspecific: special studies show a decrease in small nerve fiber density. J Am Acad Dermatol 2006; 55:519.</a></li><li><a class="nounderline abstract_t">Davis MD, Sandroni P. Lidocaine patch for pain of erythromelalgia: follow-up of 34 patients. Arch Dermatol 2005; 141:1320.</a></li><li><a class="nounderline abstract_t">Davis MD, Sandroni P. Lidocaine patch for pain of erythromelalgia. Arch Dermatol 2002; 138:17.</a></li><li><a class="nounderline abstract_t">Gales A, Chaaban B, Husson H, et al. Lidocaine-medicated plaster for treating acute autonomic and sensory neuropathy with erythromelalgia-like presentations. Rev Neurol (Paris) 2016; 172:399.</a></li><li><a class="nounderline abstract_t">Sandroni P, Davis MD. Combination gel of 1% amitriptyline and 0.5% ketamine to treat refractory erythromelalgia pain: a new treatment option? Arch Dermatol 2006; 142:283.</a></li><li><a class="nounderline abstract_t">Poterucha TJ, Weiss WT, Warndahl RA, et al. Topical amitriptyline combined with ketamine for the treatment of erythromelalgia: a retrospective study of 36 patients at Mayo Clinic. J Drugs Dermatol 2013; 12:308.</a></li><li><a class="nounderline abstract_t">Muhiddin KA, Gallen IW, Harries S, Pearce VR. The use of capsaicin cream in a case of erythromelalgia. Postgrad Med J 1994; 70:841.</a></li><li><a class="nounderline abstract_t">Davis MD, Morr CS, Warndahl RA, Sandroni P. Topically Applied Midodrine, 0.2%, an α1-Agonist, for the Treatment of Erythromelalgia. JAMA Dermatol 2015; 151:1025.</a></li><li><a class="nounderline abstract_t">Hou JL, Onajin O, Gangat N, et al. Erythromelalgia in patients with essential thrombocythemia and polycythemia vera. Leuk Lymphoma 2017; 58:715.</a></li><li><a class="nounderline abstract_t">Kurzrock R, Cohen PR. Erythromelalgia and myeloproliferative disorders. Arch Intern Med 1989; 149:105.</a></li><li><a class="nounderline abstract_t">Krishnan SG, Yesudian DP, Jayaraman M, et al. Erythromelalgia responding to aspirin. Indian J Dermatol Venereol Leprol 1996; 62:204.</a></li><li><a class="nounderline abstract_t">Davis MD, Rooke T. Erythromelalgia. Curr Treat Options Cardiovasc Med 2002; 4:207.</a></li><li><a class="nounderline abstract_t">McGraw T, Kosek P. Erythromelalgia pain managed with gabapentin. Anesthesiology 1997; 86:988.</a></li><li><a class="nounderline abstract_t">Natkunarajah J, Atherton D, Elmslie F, et al. Treatment with carbamazepine and gabapentin of a patient with primary erythermalgia (erythromelalgia) identified to have a mutation in the SCN9A gene, encoding a voltage-gated sodium channel. Clin Exp Dermatol 2009; 34:e640.</a></li><li><a class="nounderline abstract_t">Ceyhan AM, Gurses I, Yildirim M, Akkaya VB. A case of erythromelalgia: good response to treatment with gabapentin. J Drugs Dermatol 2010; 9:565.</a></li><li><a class="nounderline abstract_t">Jakob A, Creutzfeldt R, Staszewski O, et al. Primary erythromelalgia in a 12-year-old boy: positive response to sodium channel blockers despite negative SCN9A mutations. Klin Padiatr 2012; 224:309.</a></li><li><a class="nounderline abstract_t">Kakizaki A, Fujimura T, Kambayashi Y, et al. Successful treatment of adult-onset erythromelalgia with steroid pulse and pregabalin. Case Rep Dermatol 2012; 4:242.</a></li><li><a class="nounderline abstract_t">Kalava K, Roberts C, Adair JD, Raman V. Response of primary erythromelalgia to pregabalin therapy. J Clin Rheumatol 2013; 19:284.</a></li><li><a class="nounderline abstract_t">DiCaudo DJ, Kelley LA. Alleviation of erythromelalgia with venlafaxine. Arch Dermatol 2004; 140:621.</a></li><li><a class="nounderline abstract_t">Herskovitz S, Loh F, Berger AR, Kucherov M. Erythromelalgia: association with hereditary sensory neuropathy and response to amitriptyline. Neurology 1993; 43:621.</a></li><li><a class="nounderline abstract_t">Mørk C, Salerud EG, Asker CL, Kvernebo K. The prostaglandin E1 analog misoprostol reduces symptoms and microvascular arteriovenous shunting in erythromelalgia-a double-blind, crossover, placebo-compared study. J Invest Dermatol 2004; 122:587.</a></li><li><a class="nounderline abstract_t">Rudikoff D, Jaffe IA. Erythromelalgia: response to serotonin reuptake inhibitors. J Am Acad Dermatol 1997; 37:281.</a></li><li><a class="nounderline abstract_t">Cregg R, Cox JJ, Bennett DL, et al. Mexiletine as a treatment for primary erythromelalgia: normalization of biophysical properties of mutant L858F NaV 1.7 sodium channels. Br J Pharmacol 2014; 171:4455.</a></li><li><a class="nounderline abstract_t">Elgueta F, de la Cuadra-Fontaine JC, Clede L, et al. Erythromelagia: a rare and hard-to-treat condition: a 9-year-old boy responsive to intravenous lidocaine and oral mexilitene. Pain Med 2013; 14:311.</a></li><li><a class="nounderline abstract_t">Iqbal J, Bhat MI, Charoo BA, et al. Experience with oral mexiletine in primary erythromelalgia in children. Ann Saudi Med 2009; 29:316.</a></li><li><a class="nounderline abstract_t">Choi JS, Zhang L, Dib-Hajj SD, et al. Mexiletine-responsive erythromelalgia due to a new Na(v)1.7 mutation showing use-dependent current fall-off. Exp Neurol 2009; 216:383.</a></li><li><a class="nounderline abstract_t">Nathan A, Rose JB, Guite JW, et al. Primary erythromelalgia in a child responding to intravenous lidocaine and oral mexiletine treatment. Pediatrics 2005; 115:e504.</a></li><li><a class="nounderline abstract_t">Jang HS, Jung D, Kim S, et al. A case of primary erythromelalgia improved by mexiletine. Br J Dermatol 2004; 151:708.</a></li><li><a class="nounderline abstract_t">Kuhnert SM, Phillips WJ, Davis MD. Lidocaine and mexiletine therapy for erythromelalgia. Arch Dermatol 1999; 135:1447.</a></li><li><a class="nounderline abstract_t">Fischer TZ, Gilmore ES, Estacion M, et al. A novel Nav1.7 mutation producing carbamazepine-responsive erythromelalgia. Ann Neurol 2009; 65:733.</a></li><li><a class="nounderline abstract_t">Cohen JS. Erythromelalgia: new theories and new therapies. J Am Acad Dermatol 2000; 43:841.</a></li><li><a class="nounderline abstract_t">Chan MK, Tucker AT, Madden S, et al. Erythromelalgia: an endothelial disorder responsive to sodium nitroprusside. Arch Dis Child 2002; 87:229.</a></li><li><a class="nounderline abstract_t">Stone JD, Rivey MP, Allington DR. Nitroprusside treatment of erythromelalgia in an adolescent female. Ann Pharmacother 1997; 31:590.</a></li><li><a class="nounderline abstract_t">Ozsoylu S, Coşkun T. Sodium nitroprusside treatment in erythromelalgia. Eur J Pediatr 1984; 141:185.</a></li><li><a class="nounderline abstract_t">Ozsoylu S, Caner H, Gökalp A. Successful treatment of erythromelalgia with sodium nitroprusside. J Pediatr 1979; 94:619.</a></li><li><a class="nounderline abstract_t">Cohen JS. High-dose oral magnesium treatment of chronic, intractable erythromelalgia. Ann Pharmacother 2002; 36:255.</a></li><li><a class="nounderline abstract_t">Sakakibara R, Fukutake T, Kita K, Hattori T. Treatment of primary erythromelalgia with cyproheptadine. J Auton Nerv Syst 1996; 58:121.</a></li><li><a class="nounderline abstract_t">Moody S, Pacheco S, Butler IJ, Koenig MK. Secondary erythromelalgia successfully treated with intravenous immunoglobulin. J Child Neurol 2012; 27:922.</a></li><li><a class="nounderline abstract_t">Pagani-Estévez GL, Sandroni P, Davis MD, Watson JC. Erythromelalgia: Identification of a corticosteroid-responsive subset. J Am Acad Dermatol 2017; 76:506.</a></li><li><a class="nounderline abstract_t">Stricker LJ, Green CR. Resolution of refractory symptoms of secondary erythermalgia with intermittent epidural bupivacaine. Reg Anesth Pain Med 2001; 26:488.</a></li><li><a class="nounderline abstract_t">Mohr M, Schneider K, Grosche M, Hildebrandt J. [Cervical epidural infusion of morphine and bupivacaine in severe erythromelalgia]. Anasthesiol Intensivmed Notfallmed Schmerzther 1994; 29:371.</a></li><li><a class="nounderline abstract_t">D'Angelo R, Cohen IT, Brandom BW. Continuous epidural infusion of bupivacaine and fentanyl for erythromelalgia in an adolescent. Anesth Analg 1992; 74:142.</a></li><li><a class="nounderline abstract_t">Zhang L, Wang WH, Li LF, et al. Long-term remission of primary erythermalgia with R1150W polymorphism in SCN9A after chemical lumbar sympathectomy. Eur J Dermatol 2010; 20:763.</a></li><li><a class="nounderline abstract_t">Seishima M, Kanoh H, Izumi T, et al. A refractory case of secondary erythermalgia successfully treated with lumbar sympathetic ganglion block. Br J Dermatol 2000; 143:868.</a></li><li><a class="nounderline abstract_t">Cerci FB, Kapural L, Yosipovitch G. Intractable erythromelalgia of the lower extremities successfully treated with lumbar sympathetic block. J Am Acad Dermatol 2013; 69:e270.</a></li><li><a class="nounderline abstract_t">Nakajima Y, Koizumi K, Hirata T, et al. Successful thoracoscopic sympathectomy for primary erythromelalgia in the upper extremities. Jpn J Thorac Cardiovasc Surg 2004; 52:524.</a></li><li><a class="nounderline abstract_t">Shiga T, Sakamoto A, Koizumi K, Ogawa R. Endoscopic thoracic sympathectomy for primary erythromelalgia in the upper extremities. Anesth Analg 1999; 88:865.</a></li><li><a class="nounderline abstract_t">Wang WH, Zhang L, Dong GX, et al. Chemical lumbar sympathectomy in the treatment of recalcitrant erythromelalgia. J Vasc Surg 2018; 68:1897.</a></li><li><a class="nounderline abstract_t">Durosaro O, Davis MD, Hooten WM, Kerkvliet JL. Intervention for erythromelalgia, a chronic pain syndrome: comprehensive pain rehabilitation center, Mayo Clinic. Arch Dermatol 2008; 144:1578.</a></li></ol></div><div id="topicVersionRevision">Topic 13766 Version 8.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18713229" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Incidence of erythromelalgia: a population-based study in Olmsted County, Minnesota.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22247059" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Erythromelalgia: Incidence and clinical experience in a single centre in Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22247059" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Erythromelalgia: Incidence and clinical experience in a single centre in Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23762561" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Erythromelalgia? A clinical study of people who experience red, hot, painful feet in the community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21798623" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Pediatric erythromelalgia: a retrospective review of 32 cases evaluated at Mayo Clinic over a 37-year period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10724194" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Natural history of erythromelalgia: presentation and outcome in 168 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19078553" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Neurophysiologic and vascular studies in erythromelalgia: a retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14568838" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Erythromelalgia: vasculopathy, neuropathy, or both? A prospective study of vascular and neurophysiologic studies in erythromelalgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10733667" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Microvascular arteriovenous shunting is a probable pathogenetic mechanism in erythromelalgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12406343" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Reduced skin capillary density during attacks of erythromelalgia implies arteriovenous shunting as pathogenetic mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17178984" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Thermoregulatory sweat testing in patients with erythromelalgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22369570" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Results of computer-assisted sensory evaluation in 41 patients with erythromelalgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27926760" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Epidermal Nerve Fiber Quantification in Patients With Erythromelalgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Familial erythromelalgia: genetic and physiologic observations (abstract)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1536168" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Autosomal dominant erythromelalgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15385606" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Electrophysiological properties of mutant Nav1.7 sodium channels in a painful inherited neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26920677" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Inherited erythromelalgia due to mutations in SCN9A: natural history, clinical phenotype and somatosensory profile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23129781" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Infrequent SCN9A mutations in congenital insensitivity to pain and erythromelalgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29911575" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Exonic mutations in SCN9A (NaV1.7) are found in a minority of patients with erythromelalgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30416015" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Pediatric Erythromelalgia and SCN9A Mutations: Systematic Review and Single-Center Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29678386" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Facial erythromelalgia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16924077" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Between episodes of erythromelalgia: a spectrum of colors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23768296" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Immersion foot associated with the overuse of ice, cold water, and fans: a distinctive clinical presentation complicating the syndrome of erythromelalgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16908366" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Histopathologic findings in primary erythromelalgia are nonspecific: special studies show a decrease in small nerve fiber density.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16230578" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Lidocaine patch for pain of erythromelalgia: follow-up of 34 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11790162" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Lidocaine patch for pain of erythromelalgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27158041" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Lidocaine-medicated plaster for treating acute autonomic and sensory neuropathy with erythromelalgia-like presentations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16549702" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Combination gel of 1% amitriptyline and 0.5% ketamine to treat refractory erythromelalgia pain: a new treatment option?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23545913" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Topical amitriptyline combined with ketamine for the treatment of erythromelalgia: a retrospective study of 36 patients at Mayo Clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7824425" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The use of capsaicin cream in a case of erythromelalgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25946117" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Topically Applied Midodrine, 0.2%, anα1-Agonist, for the Treatment of Erythromelalgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27684959" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Erythromelalgia in patients with essential thrombocythemia and polycythemia vera.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2643412" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Erythromelalgia and myeloproliferative disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20948053" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Erythromelalgia responding to aspirin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12003720" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Erythromelalgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9105243" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Erythromelalgia pain managed with gabapentin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19549232" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Treatment with carbamazepine and gabapentin of a patient with primary erythermalgia (erythromelalgia) identified to have a mutation in the SCN9A gene, encoding a voltage-gated sodium channel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20480803" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A case of erythromelalgia: good response to treatment with gabapentin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22170168" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Primary erythromelalgia in a 12-year-old boy: positive response to sodium channel blockers despite negative SCN9A mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23275767" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Successful treatment of adult-onset erythromelalgia with steroid pulse and pregabalin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23872544" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Response of primary erythromelalgia to pregabalin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15148116" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Alleviation of erythromelalgia with venlafaxine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8451013" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Erythromelalgia: association with hereditary sensory neuropathy and response to amitriptyline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15086539" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The prostaglandin E1 analog misoprostol reduces symptoms and microvascular arteriovenous shunting in erythromelalgia-a double-blind, crossover, placebo-compared study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9270523" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Erythromelalgia: response to serotonin reuptake inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24866741" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Mexiletine as a treatment for primary erythromelalgia: normalization of biophysical properties of mutant L858F NaV 1.7 sodium channels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23368881" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Erythromelagia: a rare and hard-to-treat condition: a 9-year-old boy responsive to intravenous lidocaine and oral mexilitene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19584578" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Experience with oral mexiletine in primary erythromelalgia in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19162012" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Mexiletine-responsive erythromelalgia due to a new Na(v)1.7 mutation showing use-dependent current fall-off.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15741349" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Primary erythromelalgia in a child responding to intravenous lidocaine and oral mexiletine treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15377366" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : A case of primary erythromelalgia improved by mexiletine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10606048" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Lidocaine and mexiletine therapy for erythromelalgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19557861" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : A novel Nav1.7 mutation producing carbamazepine-responsive erythromelalgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11050591" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Erythromelalgia: new theories and new therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12193436" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Erythromelalgia: an endothelial disorder responsive to sodium nitroprusside.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9161655" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Nitroprusside treatment of erythromelalgia in an adolescent female.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6698066" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Sodium nitroprusside treatment in erythromelalgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/430305" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Successful treatment of erythromelalgia with sodium nitroprusside.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11847944" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : High-dose oral magnesium treatment of chronic, intractable erythromelalgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8740669" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Treatment of primary erythromelalgia with cyproheptadine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22156790" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Secondary erythromelalgia successfully treated with intravenous immunoglobulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28413058" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Erythromelalgia: Identification of a corticosteroid-responsive subset.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11561273" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Resolution of refractory symptoms of secondary erythermalgia with intermittent epidural bupivacaine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7999944" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : [Cervical epidural infusion of morphine and bupivacaine in severe erythromelalgia].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1734777" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Continuous epidural infusion of bupivacaine and fentanyl for erythromelalgia in an adolescent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20959280" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Long-term remission of primary erythermalgia with R1150W polymorphism in SCN9A after chemical lumbar sympathectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11069475" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : A refractory case of secondary erythermalgia successfully treated with lumbar sympathetic ganglion block.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24124862" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Intractable erythromelalgia of the lower extremities successfully treated with lumbar sympathetic block.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15609644" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Successful thoracoscopic sympathectomy for primary erythromelalgia in the upper extremities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10195539" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Endoscopic thoracic sympathectomy for primary erythromelalgia in the upper extremities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30126782" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Chemical lumbar sympathectomy in the treatment of recalcitrant erythromelalgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19075140" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Intervention for erythromelalgia, a chronic pain syndrome: comprehensive pain rehabilitation center, Mayo Clinic.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
